Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Clinical trial NCT07466303 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07466303
Sponsor: Xijing Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Start date: 2026-03-25
Primary completion: 2028-02-01
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.